Cargando…

Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren’s syndrome

BACKGROUND: The aim of the study was to reassess the prevalence and characteristics of human T lymphotropic virus type I (HTLV-I)-associated Sjögren’s syndrome (SS) and SS in HTLV-I-associated myelopathy (HAM) based on the American European Consensus Group (AECG) criteria in HTLV-I endemic area, Nag...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Hideki, Shimizu, Toshimasa, Takagi, Yukinori, Takahashi, Yoshiko, Horai, Yoshiro, Nakashima, Yoshikazu, Sato, Shuntaro, Shiraishi, Hirokazu, Nakamura, Tatsufumi, Fukuoka, Junya, Nakamura, Takashi, Kawakami, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634153/
https://www.ncbi.nlm.nih.gov/pubmed/26537778
http://dx.doi.org/10.1186/s12891-015-0773-1
_version_ 1782399301841846272
author Nakamura, Hideki
Shimizu, Toshimasa
Takagi, Yukinori
Takahashi, Yoshiko
Horai, Yoshiro
Nakashima, Yoshikazu
Sato, Shuntaro
Shiraishi, Hirokazu
Nakamura, Tatsufumi
Fukuoka, Junya
Nakamura, Takashi
Kawakami, Atsushi
author_facet Nakamura, Hideki
Shimizu, Toshimasa
Takagi, Yukinori
Takahashi, Yoshiko
Horai, Yoshiro
Nakashima, Yoshikazu
Sato, Shuntaro
Shiraishi, Hirokazu
Nakamura, Tatsufumi
Fukuoka, Junya
Nakamura, Takashi
Kawakami, Atsushi
author_sort Nakamura, Hideki
collection PubMed
description BACKGROUND: The aim of the study was to reassess the prevalence and characteristics of human T lymphotropic virus type I (HTLV-I)-associated Sjögren’s syndrome (SS) and SS in HTLV-I-associated myelopathy (HAM) based on the American European Consensus Group (AECG) criteria in HTLV-I endemic area, Nagasaki prefecture. METHODS: The 349 patients who underwent a minor salivary gland biopsy (MSGB) for suspected SS were retrospectively classified by AECG classification criteria and divided with or without anti-HTLV-I antibody. RESULTS: The HTLV-I data-available 294 patients were investigated. One hundred-seventy patients were classified as SS and 26.5 % were HTLV-I-seropositive. We have included 26 patients with HTLV-I-associated myelopathy (HAM) and 38.5 % were classified as having SS. The prevalences of ANA and anti-SS-A/Ro antibody of HAM + SS were significantly low compared to the HTLV-I asymptomatic carriers (AC) with SS and the HTLV-I-seronegative SS patients, although lacrimal dysfunction tended to be high in HAM + SS and significantly high in AC + SS patients compared with the patients with HTLV-I-seronegative SS. The focus scores of MSGB in the HAM + SS patients were similar to those of the AC + SS patients and the HTLV-I-seronegative patients with SS. Among the MSGB-positive patients, there was a low prevalence of ANA in the HAM + SS patients. Similar results were obtained in case of anti-SS-A/Ro or SS-B/La antibody. CONCLUSION: In HTLV-I endemic area, high prevalence of anti-HTLV-I antibody among SS as well as the characteristics of HAM + SS and AC + SS was still determined by AECG classification criteria.
format Online
Article
Text
id pubmed-4634153
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46341532015-11-06 Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren’s syndrome Nakamura, Hideki Shimizu, Toshimasa Takagi, Yukinori Takahashi, Yoshiko Horai, Yoshiro Nakashima, Yoshikazu Sato, Shuntaro Shiraishi, Hirokazu Nakamura, Tatsufumi Fukuoka, Junya Nakamura, Takashi Kawakami, Atsushi BMC Musculoskelet Disord Research Article BACKGROUND: The aim of the study was to reassess the prevalence and characteristics of human T lymphotropic virus type I (HTLV-I)-associated Sjögren’s syndrome (SS) and SS in HTLV-I-associated myelopathy (HAM) based on the American European Consensus Group (AECG) criteria in HTLV-I endemic area, Nagasaki prefecture. METHODS: The 349 patients who underwent a minor salivary gland biopsy (MSGB) for suspected SS were retrospectively classified by AECG classification criteria and divided with or without anti-HTLV-I antibody. RESULTS: The HTLV-I data-available 294 patients were investigated. One hundred-seventy patients were classified as SS and 26.5 % were HTLV-I-seropositive. We have included 26 patients with HTLV-I-associated myelopathy (HAM) and 38.5 % were classified as having SS. The prevalences of ANA and anti-SS-A/Ro antibody of HAM + SS were significantly low compared to the HTLV-I asymptomatic carriers (AC) with SS and the HTLV-I-seronegative SS patients, although lacrimal dysfunction tended to be high in HAM + SS and significantly high in AC + SS patients compared with the patients with HTLV-I-seronegative SS. The focus scores of MSGB in the HAM + SS patients were similar to those of the AC + SS patients and the HTLV-I-seronegative patients with SS. Among the MSGB-positive patients, there was a low prevalence of ANA in the HAM + SS patients. Similar results were obtained in case of anti-SS-A/Ro or SS-B/La antibody. CONCLUSION: In HTLV-I endemic area, high prevalence of anti-HTLV-I antibody among SS as well as the characteristics of HAM + SS and AC + SS was still determined by AECG classification criteria. BioMed Central 2015-11-04 /pmc/articles/PMC4634153/ /pubmed/26537778 http://dx.doi.org/10.1186/s12891-015-0773-1 Text en © Nakamura et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Nakamura, Hideki
Shimizu, Toshimasa
Takagi, Yukinori
Takahashi, Yoshiko
Horai, Yoshiro
Nakashima, Yoshikazu
Sato, Shuntaro
Shiraishi, Hirokazu
Nakamura, Tatsufumi
Fukuoka, Junya
Nakamura, Takashi
Kawakami, Atsushi
Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren’s syndrome
title Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren’s syndrome
title_full Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren’s syndrome
title_fullStr Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren’s syndrome
title_full_unstemmed Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren’s syndrome
title_short Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren’s syndrome
title_sort reevaluation for clinical manifestations of htlv-i-seropositive patients with sjögren’s syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634153/
https://www.ncbi.nlm.nih.gov/pubmed/26537778
http://dx.doi.org/10.1186/s12891-015-0773-1
work_keys_str_mv AT nakamurahideki reevaluationforclinicalmanifestationsofhtlviseropositivepatientswithsjogrenssyndrome
AT shimizutoshimasa reevaluationforclinicalmanifestationsofhtlviseropositivepatientswithsjogrenssyndrome
AT takagiyukinori reevaluationforclinicalmanifestationsofhtlviseropositivepatientswithsjogrenssyndrome
AT takahashiyoshiko reevaluationforclinicalmanifestationsofhtlviseropositivepatientswithsjogrenssyndrome
AT horaiyoshiro reevaluationforclinicalmanifestationsofhtlviseropositivepatientswithsjogrenssyndrome
AT nakashimayoshikazu reevaluationforclinicalmanifestationsofhtlviseropositivepatientswithsjogrenssyndrome
AT satoshuntaro reevaluationforclinicalmanifestationsofhtlviseropositivepatientswithsjogrenssyndrome
AT shiraishihirokazu reevaluationforclinicalmanifestationsofhtlviseropositivepatientswithsjogrenssyndrome
AT nakamuratatsufumi reevaluationforclinicalmanifestationsofhtlviseropositivepatientswithsjogrenssyndrome
AT fukuokajunya reevaluationforclinicalmanifestationsofhtlviseropositivepatientswithsjogrenssyndrome
AT nakamuratakashi reevaluationforclinicalmanifestationsofhtlviseropositivepatientswithsjogrenssyndrome
AT kawakamiatsushi reevaluationforclinicalmanifestationsofhtlviseropositivepatientswithsjogrenssyndrome